ANVS Stock Summary and Trading Ideas (Annovis Bio | NYSE:ANVS)

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Annovis Bio trades on the NYSE stock market under the symbol ANVS.

As of November 6, 2026, ANVS stock price climbed to $0.84 with 8,818,756 million shares trading.

ANVS has a beta of 2.23, meaning it tends to be more sensitive to market movements. ANVS has a correlation of 0.07 to the broad based SPY ETF.

ANVS has a market cap of $36.35 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ANVS traded as high as $22.49 and as low as $.62.

The top ETF exchange traded funds that ANVS belongs to (by Net Assets): VTI, VXF, IWC, BUSM.

ANVS has underperformed the market in the last year with a price return of -57.5% while the SPY ETF gained +10.8%. ANVS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -54.6% and -15.5%, respectively, while the SPY returned -4.1% and -3.2%, respectively.

ANVS support price is $.63 and resistance is $.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANVS shares will trade within this expected range on the day.